Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …

CYP2C9 is one of the most abundant CYP enzymes in the human liver (∼ 20% of hepatic
total CYP content). CYP2C9 metabolizes approximately 20% clinical drugs (> 120 drugs) …

Cytochrome P450 (CYP) 2C9 has been a relatively neglected member of the human CYP2C
family. Over the period from 2000 through 2003, PubMed searches with the key word …

Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60
clinical drugs. A number of active site residues in CYP2C8 have been identified based on …

Genetic polymorphisms in CYP2C8 can influence the metabolism of important therapeutic
agents and cause interindividual variation in drug response and toxicity. The significance of …

CYP2D6 accounts for only a small percentage of total hepatic CYPs (100) with significant
polymorphisms. A number of drugs acting on the central nervous system and cardiovascular …

The cytochrome P450 (CYP) family is composed of monooxygenases, which mediate the
metabolism of xenobiotics and endogenous compounds. The characterization of the …

A series of six site-directed mutants of CYP 2C9 were constructed with the aim to better
define the amino acid residues that play a critical role in substrate selectivity of CYP 2C9 …

Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) is a phase I metabolizing
enzyme that plays an integral role in the biotransformation of structurally diverse xenobiotics …

▪ Abstract CYP2C9 is a major cytochrome P450 enzyme that is involved in the metabolic
clearance of a wide variety of therapeutic agents, including nonsteroidal antiinflammatories …